Published 2 days ago • loading... • Updated 1 day ago

Data at Heart Rhythm 2026 highlight key Boston Scientific therapies

On Sunday, Boston Scientific Corporation announced clinical data for its FARAPULSE PFA Platform and WATCHMAN LAAC devices at the Heart Rhythm Society annual meeting in Chicago.
The randomized AVANT GUARD trial met all safety and effectiveness endpoints, demonstrating statistical superiority of PFA over anti-arrhythmic drugs with significantly higher primary effectiveness.
Results showed PFA achieved 56.0% effectiveness at 12 months versus 30.1% for drug treatment; separately, a CHAMPION-AF sub-analysis confirmed WATCHMAN FLX provided significant bleeding protection.
J.P. Morgan analyst Robbie Marcus noted Sunday that Medtronic remains competitive, as physicians increasingly adopt its technology amid the intensifying $16 billion global electrophysiology market.
Kenneth Stein, M.D., senior vice president and global chief medical officer at Boston Scientific, said the data "reflect the continued momentum of our cardiovascular portfolio," positioning the PFA platform for expansion into complex patient populations as persistent AFib reaches a $1 billion market by 2028.

Insights by Ground AI

21 Articles

4 studies to know from HRS 2026

Boston Scientific, Abbott and Medtronic shared new cardiac device data at the annual Heart Rhythm Society meeting, where market share shifts in pulsed field ablation were on analysts’ minds.

1 day ago

Read Full Article

WKOW

+16 Reposted by 16 other sources

Center

Data at Heart Rhythm 2026 highlight key Boston Scientific therapies

Positive data for FARAPULSE™ Pulsed Field Ablation and WATCHMAN™ LAAC Devices underscore therapy safety and effectiveness in late-breaking clinical trial sessions

2 days ago

Read Full Article

Medical Device Network

Reposted by

Clinical Trials Arena

HRS 2026: Medtronic, Boston Scientific and Abbott debut key PFA data

New data on the pulsed-field ablation (PFA) device class debuts at HRS 2026 as the field catches the eye of several large medtech companies.The post HRS 2026: Medtronic, Boston Scientific and Abbott debut key PFA data appeared first on Medical Device Network.

1 day ago

Read Full Article